|
시장보고서
상품코드
1566359
세계의 혈장 프로테아제 C1 억제제 시장 : 규모, 점유율, 동향, 산업 분석 보고서 - 약제 클래스별, 제형별, 유통 채널별, 지역별 시장 예측(2024-2032년)Plasma Protease C1-inhibitor Market Size, Share, Trends, and Industry Analysis Report: By Drug Class, Dosage Form, Distribution Channel, and Region - Market Forecast, 2024 - 2032 |
||||||
Polaris Market Research의 최근 조사에 따르면, 혈장 프로테아제 C1 억제제 세계 시장 규모는 2032년까지 79억 6,000만 달러에 이를 것으로 예상됩니다. 이 보고서는 현재 시장 역학을 상세하게 통찰하고 미래 시장 성장에 대한 분석을 제공합니다.
혈장 프로테아제 C1 억제제(C1-INH) 시장은 제제, 안전성, 치료 효과, 적응 확대 등의 발전으로 최근 몇 년간 상당한 기술 혁신을 이루고 있습니다. 정맥내 투여에서 피하 투여로의 전환은 큰 비약을 의미하고, 편리성이 향상되고, 환자의 컴플라이언스가 증가할 수 있습니다. 동시에, 정제 공정의 개선은 C1-INH 제형의 안전성 프로파일을 강화하고, 부작용을 최소화하고, 치료 효과를 극대화합니다.
기존의 C1-INH 보충 요법에 머무르지 않는 새로운 작용기전에 대한 현재 진행 중인 연구는 치료 옵션을 넓히고 유전성 혈관성 부종(HAE) 및 관련 질환의 광범위한 환자를 수용할 수 있습니다. 예를 들어, 2024년 6월, 암스테르담 UMC의 내과 의사와 연구자에 의해 보고된 바와 같이, 두 신약, donidalorsen과 sebetralstat이 유전성 혈관성 부종의 치료에 유망한 결과를 보였습니다.
혈장 프로테아제 C1 억제제(C1-INH) 시장은 세계 HAE의 진단 증가에 견인된 수요 증가를 특징으로합니다. 이 드문 유전성 질환은 효과적인 C1-INH 보충 요법을 필요로 하고 치료 옵션의 지속적인 발전을 촉진합니다. 전달 방법과 제형의 혁신은 환자의 편의성과 어드히어런스를 높이는 것을 목표로 하는 반면, 지리적 확장 노력은 이러한 특수 요법에 대한 접근을 세계적으로 개선하는 것을 목표로 하고 있습니다. 경쟁 구도은 여전히 활발하며 제약 회사는 연구 개발에 투자하고 있으며 시장 성장과 새로운 치료법의 채택을 촉진하는 규제 이니셔티브에 의해 지원되고 있습니다. 환자 중심의 프로그램과 광고 활동은 HAE와 함께 사는 사람들의 결과와 삶의 질 향상에 더욱 기여하며 C1-INH 시장의 미래 궤도를 형성하고 있습니다.
혈장 프로테아제 C1 억제제 시장 보고서 하이라이트
2023년에는 C1 억제제가 시장을 선도하고 주요 기업에 의한 지속적인 R&D 노력으로 선택적 브라지키닌 B2 수용체 길항제가 가장 빠른 성장을 보일 것으로 예상됩니다.
동결건조제제는 안정성, 보존기간 연장, 보관·수송의 편리성에 의해 C1 억제제 치료에 선호되어 환자와 의료 제공업체에게 효능과 간편성을 확보할 수 있기 때문에 시장을 석권했습니다.
병원 약국이 혈장 프로테아제 C1 억제제 시장을 선도한 것은 광범위한 접근성, 규정 준수, 혈장 프로테아제 C1 억제제와 같은 특수 요법의 효과적인 관리 때문입니다.
북미는 엄청난 건강 관리 지출, 고급 인프라, 광범위한 조사, 유전성 혈관성 부종과 같은 희귀질환에 대한 혈장 프로테아제 C1 억제제 치료의 상당한 사용으로 2023년 시장을 선도했습니다.
혈장 프로테아제 C1 억제제의 세계 주요 기업은 BioCryst Pharmaceuticals, Inc., CENTOGENE NV, CSL, Fresenius Kabi, Ionis Pharmaceuticals, Inc., KalVista Pharmaceuticals, Pharming, Sanquin, Shire plc, Takeda Pharmaceutical Company Limited. 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 세계의 혈장 프로테아제 C1 억제제 시장 인사이트
- 용도 스냅샷
- 혈장 프로테아제 C1 억제제 시장 역학
- 성장 촉진요인과 기회
- 임상시험과 조사활동 증가가 시장 성장을 견인
- 헬스케어 분야의 지출 증가가 혈장 프로테아제 C1 억제제 시장의 성장을 견인
- 억제요인과 과제
- 치료비의 상승
- 성장 촉진요인과 기회
- PESTEL 분석
- 혈장 프로테아제 C1 억제제 시장의 응용 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 혈장 프로테아제 C1 억제제 시장 : 약제 클래스별
- 주요 조사 결과
- 소개
- C1 억제제
- 칼리크레인 억제제
- 선택적 브라디키닌 B2 수용체 길항제
제6장 세계의 혈장 프로테아제 C1 억제제 시장 : 투여형별
- 주요 조사 결과
- 소개
- 동결건조
- 주사제
제7장 세계의 혈장 프로테아제 C1 억제제 시장 : 유통 채널별
- 주요 조사 결과
- 소개
- 병원 약국
- 소매 약국
- 온라인 약국
제8장 세계의 혈장 프로테아제 C1 억제제 시장 : 지역별
- 주요 조사 결과
- 소개
- 혈장 프로테아제 C1 억제제 시장 평가:지역, 2019-2032년
- 북미
- 북미 : 약제 클래스별, 2019-2032년
- 북미 : 제형별, 2019-2032년
- 북미 : 유통 채널별, 2019-2032년
- 미국
- 캐나다
- 유럽
- 유럽 : 약제 클래스별, 2019-2032년
- 유럽 : 제형별, 2019-2032년
- 유럽 : 유통 채널별, 2019-2032년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양: 약제 클래스별, 2019-2032년
- 아시아태평양:제형별, 2019-2032년
- 아시아태평양: 유통 채널별, 2019-2032년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 약제 클래스별, 2019-2032년
- 중동 및 아프리카 : 제형별, 2019-2032년
- 중동 및 아프리카 : 유통 채널별, 2019-2032년
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 약제 클래스별, 2019-2032년
- 라틴아메리카 : 제형별, 2019-2032년
- 라틴아메리카 : 유통 채널별, 2019-2032년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제9장 경쟁 구도
- 확대와 인수 분석
- 확대
- 인수
- 제휴/협업/합의/공개
제10장 기업 프로파일
- BioCryst Pharmaceuticals, Inc.
- CENTOGENE NV
- CSL
- Fresenius Kabi
- Ionis Pharmaceuticals, Inc.
- KalVista Pharmaceuticals
- Pharming
- Sanquin
- Shire plc
- Takeda Pharmaceutical Company Limited
The global plasma protease C1-inhibitor market size is expected to reach USD 7.96 billion by 2032, according to a new study by Polaris Market Research. The report "Global Plasma Protease C1-inhibitor Market Size, Share, Trends, Industry Analysis Report: By Drug Class (C1-inhibitors, Kallikrein Inhibitor, and Selective Bradykinin B2 Receptor), Dosage Form, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2024 - 2032." gives a detailed insight into current market dynamics and provides analysis on future market growth.
The market for plasma protease C1-inhibitor (C1-INH) has witnessed substantial innovation in recent years, driven by advancements in formulation, safety, therapeutic efficacy, and expanded indications. The shift from intravenous to subcutaneous administration represents a significant leap forward, offering improved convenience and potentially enhancing patient compliance. Concurrently, improvements in purification processes have bolstered the safety profiles of C1-INH products, minimized adverse reactions and maximizing therapeutic effectiveness.
Ongoing research into novel mechanisms of action beyond traditional C1-INH replacement therapy holds promise for broadening treatment options, potentially catering to a wider range of patients with hereditary angioedema (HAE) and related conditions. For instance, in June 2024, two new medicines, donidalorsen and sebetralstat, showed promising results in treating hereditary angioedema, as reported by an internist and researcher from Amsterdam UMC.
The market for plasma protease C1-inhibitor (C1-INH) is characterized by a rising demand driven by increasing diagnoses of HAE globally. This rare genetic disorder necessitates effective C1-INH replacement therapies, prompting ongoing advancements in treatment options. Innovations in delivery methods and formulations aim to enhance patient convenience and adherence, while geographic expansion efforts seek to improve access to these specialized therapies worldwide. The competitive landscape remains active with pharmaceutical companies investing in research and development, supported by regulatory initiatives that facilitate market growth and adoption of new therapies. Patient-centric programs and advocacy efforts further contribute to improving outcomes and quality of life for individuals living with HAE, shaping the future trajectory of the C1-INH market.
Plasma Protease C1-inhibitor Market Report Highlights
C1-inhibitors led the market in 2023, with selective bradykinin B2 receptor antagonists expected to show the fastest growth due to ongoing R&D efforts by key industry players.
Lyophilized segments dominated the market with their stability, extended shelf life, and convenient storage and transport, making them favored for C1-inhibitor therapy, ensuring effectiveness and ease for patients and providers.
Hospital pharmacies led the plasma protease C1-inhibitor market due to their wide accessibility, regulatory adherence, and effective management of specialized therapies such as plasma protease C1-inhibitor.
North America led the market in 2023, owing to its substantial healthcare spending, advanced infrastructure, extensive research, and significant use of plasma protease C1-inhibitor therapies for rare diseases such as hereditary angioedema.
The global key plasma protease C1-inhibitor market players include BioCryst Pharmaceuticals, Inc.; CENTOGENE N.V.; CSL; Fresenius Kabi; Ionis Pharmaceuticals, Inc.; KalVista Pharmaceuticals; Pharming; Sanquin; Shire plc; and Takeda Pharmaceutical Company Limited.
Polaris Market Research has segmented the Plasma Protease C1-inhibitor market report based on drug class, dosage form, distribution channel, and region:
By Drug Class Outlook (Revenue - USD billion, 2019 - 2032)
- C1-inhibitors
- C1-esterase Inhibitor
- Recombinant Inhibitor
- Kallikrein Inhibitor
- Selective Bradykinin B2 Receptor Antagonist
By Dosage Form Outlook (Revenue - USD billion, 2019 - 2032)
- Lyphophlised
- Injectables
By Distribution Channel Outlook (Revenue - USD billion, 2019 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Regional Outlook (Revenue - USD billion, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Australia
- Vietnam
- Rest of Asia Pacific
- Latin America
- Argentina
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
- Rest of Middle East & Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Plasma Protease C1-inhibitor Market Insights
- 4.1. Plasma Protease C1-inhibitor Market - Application Snapshot
- 4.2. Plasma Protease C1-inhibitor Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Increasing Clinical Trials and Research Initiatives is Driving the Market Growth
- 4.2.1.2. Rising Expenditure in Healthcare Sector Driving Plasma Protease C1-Inhibitor Market Growth
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High Cost of Treatment
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Plasma Protease C1-inhibitor Market Application Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Plasma Protease C1-inhibitor Market, by Drug Class
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 5.3. C1-Inhibitor
- 5.3.1. Global Plasma Protease C1-inhibitor Market, by C1-Inhibitor, by Region, 2019-2032 (USD billion)
- 5.3.1.1 C1-esterase Inhibitor
- 5.3.1.1.1 Global Plasma Protease C1-inhibitor Market, by C1-esterase Inhibitor, by Region, 2019-2032 (USD billion)
- 5.3.1.2 Recombinant Inhibitor
- 5.3.1.1.2 Global Plasma Protease C1-inhibitor Market, by Recombinant Inhibitor, by Region, 2019-2032 (USD billion)
- 5.3.1. Global Plasma Protease C1-inhibitor Market, by C1-Inhibitor, by Region, 2019-2032 (USD billion)
- 5.4. Kallikrein Inhibitor
- 5.4.1. Global Plasma Protease C1-inhibitor Market, by Kallikrein Inhibitor, by Region, 2019-2032 (USD billion)
- 5.5. Selective Bradykinin B2 Receptor Antagonist
- 5.5.1. Global Plasma Protease C1-inhibitor Market, by Selective Bradykinin B2 Receptor Antagonist, by Region, 2019-2032 (USD billion)
6. Global Plasma Protease C1-inhibitor Market, by Dosage Form
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 6.3. Lyphophlised
- 6.3.1. Global Plasma Protease C1-inhibitor Market, by Lyphophlised, by Region, 2019-2032 (USD billion)
- 6.4. Injectables
- 6.4.1. Global Plasma Protease C1-inhibitor Market, by Injectables, by Region, 2019-2032 (USD billion)
7. Global Plasma Protease C1-inhibitor Market, by Distribution Channel
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 7.3. Hospital Pharmacies
- 7.3.1. Global Plasma Protease C1-inhibitor Market, by Hospital Pharmacies, By Region, 2019-2032 (USD billion)
- 7.4. Retail Pharmacies
- 7.4.1. Global Plasma Protease C1-inhibitor Market, by Retail Pharmacies, By Region, 2019-2032 (USD billion)
- 7.5. Online Pharmacies
- 7.5.1. Global Plasma Protease C1-inhibitor Market, by Online Pharmacies, By Region, 2019-2032 (USD billion)
8. Global Plasma Protease C1-inhibitor Market, by Geography
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. Plasma Protease C1-inhibitor Market Assessment, By Geography, 2019-2032 (USD billion)
- 8.3. Plasma Protease C1-inhibitor Market - North America
- 8.3.1. North America: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.3.2. North America: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.3.3. North America: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.3.4. Plasma Protease C1-inhibitor Market - U.S.
- 8.3.4.1. U.S.: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.3.4.2. U.S.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.3.4.3. U.S.: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.3.5. Plasma Protease C1-inhibitor Market - Canada
- 8.3.5.1. Canada: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.3.5.2. Canada.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.3.5.3. Canada: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.4. Plasma Protease C1-inhibitor Market - Europe
- 8.4.1. Europe: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.4.2. Europe.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.4.3. Europe: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.4.4. Plasma Protease C1-inhibitor Market - UK
- 8.4.4.1. UK: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.4.4.2. UK.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.4.4.3. UK: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.4.5. Plasma Protease C1-inhibitor Market - France
- 8.4.5.1. France: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.4.5.2. France.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.4.5.3. France: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.4.6. Plasma Protease C1-inhibitor Market - Germany
- 8.4.6.1. Germany: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.4.6.2. Germany.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.4.6.3. Germany: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.4.7. Plasma Protease C1-inhibitor Market - Italy
- 8.4.7.1. Italy: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.4.7.2. Italy.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.4.7.3. Italy: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.4.8. Plasma Protease C1-inhibitor Market - Spain
- 8.4.8.1. Spain: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.4.8.2. Spain.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.4.8.3. Spain: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.4.9. Plasma Protease C1-inhibitor Market - Netherlands
- 8.4.9.1. Netherlands: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.4.9.2. Netherlands.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.4.9.3. Netherlands: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.4.10. Plasma Protease C1-inhibitor Market - Russia
- 8.4.10.1. Russia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.4.10.2. Russia.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.4.10.3. Russia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.4.11. Plasma Protease C1-inhibitor Market - Rest of Europe
- 8.4.11.1. Rest of Europe: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.4.11.2. Rest of Europe.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.4.11.3. Rest of Europe: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.5. Plasma Protease C1-inhibitor Market - Asia Pacific
- 8.5.1. Asia Pacific: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.5.2. Asia Pacific.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.5.3. Asia Pacific: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.5.4. Plasma Protease C1-inhibitor Market - China
- 8.5.4.1. China: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.5.4.2. China.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.5.4.3. China: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.5.5. Plasma Protease C1-inhibitor Market - India
- 8.5.5.1. India: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.5.5.2. India.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.5.5.3. India: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.5.6. Plasma Protease C1-inhibitor Market - Malaysia
- 8.5.6.1. Malaysia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.5.6.2. Malaysia.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.5.6.3. Malaysia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.5.7. Plasma Protease C1-inhibitor Market - Japan
- 8.5.7.1. Japan: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.5.7.2. Japan.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.5.7.3. Japan: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.5.8. Plasma Protease C1-inhibitor Market - Indonesia
- 8.5.8.1. Indonesia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.5.8.2. Indonesia.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.5.8.3. Indonesia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.5.9. Plasma Protease C1-inhibitor Market - South Korea
- 8.5.9.1. South Korea: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.5.9.2. South Korea: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.5.9.3. South Korea: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.5.10. Plasma Protease C1-inhibitor Market - Australia
- 8.5.10.1. Australia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.5.10.2. Australia: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.5.10.3. Australia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.5.11. Plasma Protease C1-inhibitor Market - Rest of Asia Pacific
- 8.5.11.1. Rest of Asia Pacific: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.5.11.2. Rest of Asia Pacific: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.5.11.3. Rest of Asia Pacific: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.6. Plasma Protease C1-inhibitor Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.6.2. Middle East & Africa.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.6.3. Middle East & Africa: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.6.4. Plasma Protease C1-inhibitor Market - Saudi Arabia
- 8.6.4.1. Saudi Arabia: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.6.4.2. Saudi Arabia.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.6.4.3. Saudi Arabia: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.6.5. Plasma Protease C1-inhibitor Market - UAE
- 8.6.5.1. UAE: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.6.5.2. UAE.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.6.5.3. UAE: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.6.6. Plasma Protease C1-inhibitor Market - Israel
- 8.6.6.1. Israel: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.6.6.2. Israel.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.6.6.3. Israel: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.6.7. Plasma Protease C1-inhibitor Market - South Africa
- 8.6.7.1. South Africa: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.6.7.2. South Africa.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.6.7.3. South Africa: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.6.8. Plasma Protease C1-inhibitor Market - Rest of Middle East & Africa
- 8.6.8.1. Rest of Middle East & Africa: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.6.8.2. Rest of Middle East & Africa: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.6.8.3. Rest of Middle East & Africa: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.7. Plasma Protease C1-inhibitor Market - Latin America
- 8.7.1. Latin America: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.7.2. Latin America.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.7.3. Latin America: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.7.4. Plasma Protease C1-inhibitor Market - Mexico
- 8.7.4.1. Mexico: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.7.4.2. Mexico.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.7.4.3. Mexico: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.7.5. Plasma Protease C1-inhibitor Market - Brazil
- 8.7.5.1. Brazil: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.7.5.2. Brazil.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.7.5.3. Brazil: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.7.6. Plasma Protease C1-inhibitor Market - Argentina
- 8.7.6.1. Argentina: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.7.6.2. Argentina.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.7.6.3. Argentina: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
- 8.7.7. Plasma Protease C1-inhibitor Market - Rest of Latin America
- 8.7.7.1. Rest of Latin America: Plasma Protease C1-inhibitor Market, by Drug Class, 2019-2032 (USD billion)
- 8.7.7.2. Rest of Latin America.: Plasma Protease C1-inhibitor Market, by Dosage Form, 2019-2032 (USD billion)
- 8.7.7.3. Rest of Latin America: Plasma Protease C1-inhibitor Market, by Distribution Channel, 2019-2032 (USD billion)
9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
- 10.1. BioCryst Pharmaceuticals, Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. CENTOGENE N.V.
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. CSL
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Fresenius Kabi
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Ionis Pharmaceuticals, Inc.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. KalVista Pharmaceuticals
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Pharming
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Sanquin
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Shire plc
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Takeda Pharmaceutical Company Limited
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
